The Global Generics & Biosimilars Awards will take place digitally on Tuesday, November 3, 2020 and reward ‘best practice’ across the generics, biosimilars and value added medicine industries, while at the same time encouraging improvements in every aspect of the way business is conducted.
Business development initiatives – such as through innovative product development, clever licensing deals or smart legal manoeuvres – are at the heart of the Global Generics & Biosimilars Awards as well as recognising the industries’ best executives and leading companies.
Every Award will effectively underscore the efforts made by the global generics and biosimilars industries to make more affordable medicines available to more people everywhere.
Although we won’t be able to meet in person, going digital will allow your entire team to virtually celebrate their achievements across the industry. Online registration is now open for the Global Generics & Biosimilars Awards.
IQVIA is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™️, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 67,000 employees, IQVIA conducts operations in more than 100 countries.
is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
In communities around the world affected by chronic poverty, conflict or disasters, easily treatable diseases can mean chronic pain, poor quality of life or even a death sentence. International Health Partners (IHP) was founded in 2003 with a vision to radically enhance access to medicine to the world’s most vulnerable people. IHP enable targeted donations of medicines from a network of over 60 healthcare companies across Europe, and coordinate the safe and responsible supply of these to disaster hit and vulnerable communities across the world. IHP are the only organisation working to this model in the UK. In the last three years IHP have sent over 8.2 million treatments, with a value of over £34.5 million.
Pharmaceutical, biotechnology, generic and medical device companies trust West and our ability to deliver consistent high-quality
C+D Data is the most comprehensive product database for the pharmacy market in the UK. We have over 1,200 manufacturers registered who list over 110,000 products with our online database cddata.co.uk. All the products registered with C+D Data are sold in the UK healthcare market including community pharmacy, hospital pharmacy, private healthcare and dispensing doctors.
If you are looking to understand which manufacturers sell what products in the UK then we can assist. C+D Data is used for a wide variety of purposes such as eProcurement, product scanning, EPOS, online pharmacy, order fulfilment, online customer portals and much more.
Aurobindo’s mission is to become the most valued Pharma partner to the World Pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products that comply with the highest regulatory standards.
In addition to being the market leader in Semi-Synthetic Penicillin’s, Aurobindo Pharma has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Anti-biotics.
Through cost effective manufacturing capabilities and a few loyal customers, the company also entered the high margin specialty generic formulations segment. Today Aurobindo Pharma has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries. A well-integrated pharma company, Aurobindo Pharma features among the top 2 Pharmaceutical companies in India in terms of consolidated revenues. Aurobindo exports to over 150 countries across the globe